Show simple item record

dc.contributor.authorAbidov, A.
dc.contributor.authorDilsizian, V.
dc.contributor.authorDoukky, R.
dc.date.accessioned2019-09-13T14:49:28Z
dc.date.available2019-09-13T14:49:28Z
dc.date.issued2019
dc.identifier.urihttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85058976396&doi=10.1007%2fs12350-018-01548-0&partnerID=40&md5=0b3d89db1a6bb63e685bdea035d29f8d
dc.identifier.urihttp://hdl.handle.net/10713/10546
dc.description.abstractPharmacologic reversal of serious or intolerable side effects (SISEs) from vasodilator stress is an important safety and comfort measure for patients experiencing such effects. While typically performed using intravenous aminophylline, recurrent shortages of this agent have led to a greater need to limit its use and consider alternative agents. This information statement provides background and recommendations addressing indications for vasodilator reversal, timing of a reversal agent, incidence of observed SISE with vasodilator stress, clinical and logistical considerations for aminophylline-based reversal, and alternative non-aminophylline based reversal protocols. Copyright 2018, The Author(s).en_US
dc.description.urihttps://doi.org/10.1007/s12350-018-01548-0en_US
dc.language.isoen-USen_US
dc.publisherSpringer New York LLCen_US
dc.relation.ispartofJournal of Nuclear Cardiology
dc.subjectMPIen_US
dc.subjectMRIen_US
dc.subjectPETen_US
dc.subjectSPECTen_US
dc.subjectvasodilatorsen_US
dc.titleAminophylline shortage and current recommendations for reversal of vasodilator stress: An ASNC information statement endorsed by SCMRen_US
dc.typeArticleen_US
dc.identifier.doi10.1007/s12350-018-01548-0
dc.identifier.pmid30574677


This item appears in the following Collection(s)

Show simple item record